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Available online xxxxBackground: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix,
an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess a possible
association and inform policy on future use of adjuvants, we conducted a multi-country study of
narcolepsy and adjuvanted pH1N1 vaccines.
Methods: We used electronic health databases to conduct a dynamic retrospective cohort study to assess
narcolepsy incidence rates (IR) before and during pH1N1 virus circulation, and after pH1N1 vaccinationsment.
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Vaccine (2018), https://doi.org/10.1016/j.vaccincampaigns in Canada, Denmark, Spain, Sweden, Taiwan, the Netherlands, and the United Kingdom. Using
a case-control study design, we evaluated the risk of narcolepsy following AS03- and MF59-adjuvanted
pH1N1 vaccines in Argentina, Canada, Spain, Switzerland, Taiwan, and the Netherlands. In the
Netherlands, we also conducted a case-coverage study in children born between 2004 and 2009.
Results: No changes in narcolepsy IRs were observed in any periods in single study sites except Sweden
and Taiwan; in Taiwan incidence increased after wild-type pH1N1 virus circulation and in Sweden (a pre-
viously identified signaling country), incidence increased after the start of pH1N1 vaccination. No asso-
ciation was observed for Arepanrix-AS03 or Focetria-MF59 adjuvanted pH1N1 vaccines and narcolepsy in
children or adults in the case-control study nor for children born between 2004 and 2009 in the
Netherlands case-coverage study for Pandemrix-AS03.
Conclusions: Other than elevated narcolepsy IRs in the period after vaccination campaigns in Sweden, we
did not find an association between AS03- or MF59-adjuvanted pH1N1 vaccines and narcolepsy in chil-
dren or adults in the sites studied, although power to evaluate the AS03-adjuvanted Pandemrix brand
vaccine was limited in our study.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In fall 2009, large-scale vaccination campaigns were imple-
mented globally in response to the influenza A (H1N1) pandemic
(pH1N1). Different inactivated monovalent vaccines were used;
the United States used unadjuvanted vaccines, whereas in Europe,
MF59-(Focetria, Novartis Vaccines and Diagnostics) and AS03-
adjuvanted (Pandemrix, GSK biologicals) vaccines were mostly
used. In Canada, AS03-adjuvanted Arepanrix (ID Biomedical Corp.,
a subsidiary of GSK Biologicals) was used. Arepanrix and Pandem-
rix had similar pH1N1 antigens and used the same AS03 adjuvant;
however, there were slight differences in the manufacturing
processes for the two vaccines. In August 2010, case reports from
Sweden and Finland emerged describing narcolepsy in children
following vaccination with Pandemrix [1–6].
Narcolepsy is a chronic debilitating sleep disorder with a sus-
pected autoimmune etiology. Genetic predisposition also appears
to play a role; narcolepsy with cataplexy (with hypocretin defi-
ciency) is highly associated with HLA-DQB1*06:02, while nar-
colepsy without cataplexy (and normal hypocretin levels) is less
associated with HLA-DQB1*06:02, but still more so than in the gen-
eral population. Narcolepsy/cataplexy is characterized by excessive
daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic
hallucinations and fragmented nighttime sleep. Symptoms often
emerge gradually and may initially be non-specific [7–10]. The
insidious onset can result in diagnostic delays of months to years,
making it challenging to study exposures that might cause or con-
tribute to disease occurrence [11].
Several European studies were initiated to rapidly evaluate the
possible association between Pandemrix-AS03 and narcolepsy
[1,2,4,5,12–18]. These studies are summarized in reviews by Ver-
straeten et al. [19], Sturkenboom [20] and Sarkanen et al. [21]. Sev-
eral studies showed an increased risk, but results were variable
within and across studies and subject to methodological challenges
due to narcolepsy epidemiology and increased awareness about
the association. Most studies focused on Pandemrix-AS03 and data
were limited on other adjuvanted pH1N1 vaccines, including
Arepanrix-AS03 and Focetria-MF59 [22,23].
To better understand the relationship between narcolepsy and
different adjuvanted pH1N1 vaccines, we organized an interna-
tional research network, including study sites within and outside
of Europe, where adjuvanted vaccines were used and little or no
substantial concerns were raised about an association with nar-
colepsy in local media. Drawing on the expertise of clinicians,
research scientists and public health officials within the network,
we implemented the Systematic Observational Method for
Narcolepsy and Influenza Immunization Assessment (SOMNIA)
study.al. Narcolepsy and adjuvanted
e.2018.08.0082. Methods
2.1. Study site selection
We used a stepwise process to identify, recruit, and select par-
ticipating study sites for incidence rates and case-control analyses.
First, we identified countries that used adjuvanted 2009 pH1N1
vaccines using information obtained from the World Health Orga-
nization and from the two vaccine manufacturers. We excluded
countries where compensation programs for narcolepsy associated
with pH1N1 vaccination existed because we believed this could
potentially bias case ascertainment with vaccinated cases poten-
tially being evaluated sooner or differently than non-vaccinated
cases. Finland, Norway and Sweden were excluded from the
case-control study on this basis. In addition, Finland and Sweden
had been signaling countries. Of note Sweden, as a signaling coun-
try was included in the incidence rate study to provide a reference
comparison, but data from Sweden were not pooled in the inci-
dence rate analysis. Working with national, regional and local
health officials, academics, and sleep centers, we assessed whether
potential study sites had acceptable availability and accessibility of
vaccination and outcome data. Israel, South Korea and Cuba, were
excluded because of lack of exposure information. Brazil was elim-
inated because obtaining timely administrative approvals was not
feasible. Finally, we engaged in discussions with prospective inves-
tigators to gauge willingness and ability to participate in the inci-
dence rate or case-control studies and confirm existence of
acceptable data and data systems to participate using the common
study protocol. After completing these steps and obtaining the nec-
essary clearances we included the final set of countries in our
analysis.
All sites used the same protocol, the same data collection mate-
rials and common analytics, but sites could implement the proto-
col based upon their local processes and health care structure.
For quality control, the study coordination team verified imple-
mentation of the protocol with all sites during monthly calls. The
data management team further verified all the data and discussed
potential biases with the sites. Sites were responsible for verifica-
tion of their results and decisions on inclusion of the data and
could access remotely the secure data sharing environment. These
distributed data management procedures have been previously
described [24].
2.2. Narcolepsy incidence rates analysis
We estimated narcolepsy incidence rates (IR) at ten study sites
(in seven countries) using population-based electronic health
record databases from general practitioners (GP) (Spain [Valenciapandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment.
Table 1
Overview of study sites for the IR, case-control and case-coverage analyses.
Study site (vaccines) IR Case-control or case-coverage
Data source Codes and algorithms Case identification Controls source pH1N1 vaccine exposure
Europe Switzerland
(Pandemrix-AS03, Focetria-
MF59)
14 hospitals & sleep centers,
no consent required
Matched in same hospital of
case, no consent required
General practitioner (GP)
medical record
Spain, Catalonia
(Pandemrix-AS03, Focetria-
MF59)
SIDIAP general
practitioners’ database
ICD-10 code G47.4 Sleep units at 13 public
hospitals until end of 2013
& also in SIDIAP. No consent
required
SIDIAP database, no consent
required
SIDIAP database
Spain, Valencia
(Pandemrix-AS03, Focetria-
MF59)
SIA regional general
practitioners’ databases
ICD-9CM codes 347.a with
Manual validation
Identified from 24 sleep
centers and electronic
registries (inpatient and
outpatient databases)
SIA general practitioners’
database, no consent
required
Obtained from electronic
registry
The Netherlands
(Pandemrix-AS03, Focetria-
MF59)
IPCI general practitioners’
databases
Free text narcolepsy &
MSLT, cases manually
validated
Four sleep centers
(academic and non-
university hospitals).
Consent required
IPCI general practitioners’
database, no consent
required
1. Electronic medical GP
records for all patients
2. For cases also from vaccina-
tion card and public health
agency to estimate com-
pleteness in GP records
The United Kingdom
(Pandemrix-AS03)
THIN general practitioners’
databases
Read codes F27.00; F270.00;
F271.00; F27z.00
Denmark
(Pandemrix-AS03)
Danish Civil Registration
System covering the
Northern and Central
Region of Jutland in
Denmark linked to Danish
National Patient Register
ICD-10 code G47.4,
inpatient, ambulatory care
and emergency room
diagnosis
Sweden Patient register at the
National board of health,
Population from population
register at Statistics Sweden
ICD-10 code G47.4,
diagnosis in and outpatient
South America Argentina
(Focetria-MF59)
13 MSLT sites, pediatric,
adult neurology and
respiratory centers in
Buenos Aires, verbal
consent
General practitioners,
verbal informed consent
conducted
Vaccination cards from cases and
controls
North America
(Canada)
Ontario
(Arepanrix-AS03)
Patient charts at sleep units
after using physician billing
claims to generate initial list
of MSLTs performed, limited
to maximum age 24
Matched from ICES
provincial database of all
residents with health
insurance, no consent
required
1. Primary care physician
(PCP), family physicians’
and pediatricians’ charts;
2. Public health unit records
(electronic databases, and
physician billing claims
data)
North America
(Canada)
Alberta
(Arepanrix-AS03)
Cases indentified and
population denominator
established with claims/
hospital record linkage
databases
ICD9-CM codes 347.a with
MSLT procedure
Manitoba
(Arepanrix-AS03)
Population-based Hospital
and Physician Claims
databases linked to
Manitoba Health Population
Registry
ICD9-CM codes 347.a with
MSLT procedure
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claims/record linkage databases (Canada [Manitoba, Alberta and
British Columbia], Denmark, Sweden, and Taiwan). Study
populations included individuals registered in the database for at
least one year prior to start of follow-up. Follow-up started at
the begining of the study period (January 1, 2003) or the date of
registration and ended at the earliest of the following: death, the
patient moving, the end of the study period (December 31, 2013)
or outcome occurrence. Cases were captured in these databases
by identifying individuals with newly diagnosed narcolepsy with
or without cataplexy. (Database codes and algorithms are shown
in Table 1). In GP databases in the Netherlands and from records
of sleep medicine specialists in Valencia, case finding algorithms
were validated using the Brighton Collaboration case definition cri-
teria for narcolepsy [25]. In other sites, we required both diagnostic
codes for narcolepsy along with reimbursement claims for a mul-
tiple sleep latency test (MSLT) to reduce the risk of false positives.
We calculated IRs by year and month and categorized them into
three periods: (1) pre-pH1N1, (2) during wild-type pH1N1 virus
circulation until the start of pH1N1 vaccination (country specific),
and (3) from the start of pH1N1 vaccination through the end of the
study in December 2013. Periods of wild-type pH1N1 virus circu-
lation and vaccination varied by sites. We stratified IRs by age
and sex and pooled aggregated person-time and case counts for
further analysis. IR data from Sweden were analyzed separately
since Sweden had been a priori identified as a signaling country,
and hence, served as a comparator for other sites in our IR analysis
[26,29]. We estimated incidence rate ratios (IRR), comparing the
two latter periods to the pre-pH1N1 period, using Poisson
regression.
2.3. Case-control analysis
Seven sites in six countries met our criteria for inclusion in the
case-control study: Argentina, Canada (Ontario), Spain (Valencia
and Catalonia), Switzerland, Taiwan, and the Netherlands (Table 1).
All sites collected information in the same electronic case report
forms (Chameleon, Erasmus Medical Center, Rotterdam, the
Netherlands). Depending on data sharing restrictions, local investi-
gators either transferred aggregated data to a secure remote
research environment for further analysis and one stage pooling
or ran the same analyses locally and transferred coefficients and
counts for inclusion in a two-stage meta-analysis (Fig. 1).
2.3.1. Cases and controls
Local investigators identified narcolepsy cases at sleep centers
using diagnosis lists or diagnostic test outcomes. InvestigatorsFig. 1. Two-stage hybrid approach for pooling case-control data from study sites.
The two-stage hybrid approach pooled case-control data to estimate an odds ratio
from European Union country sites and Argentina (b1). Odds ratios from Taiwan and
Ontario (b2 and b3) were analyzed in a subsequent meta-analytic approach
including the pooled odds ratio from European Union country sites and Argentina
(Wk = weight related to estimate bk, being the reciprocal of its variance,
R = summation operator, b = meta-analysis result for the odds ratio).
pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment.
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and classified cases into certainty levels using the Brighton Collab-
oration narcolepsy case definition [25]. Cases were included if they
were classified as Brighton Collaboration level 1–4 for persons
16 years or level 1–2 for persons <16 years, and had an MSLT
referral and a diagnosis both made after March 31, 2009 (start of
the H1N1 pandemic). Brighton Collaboration classification desig-
nates level 1 as the highest level of diagnostic certainty; levels have
different cut-off values for MSLT results starting at age 16 years,
which were maintained in the study. Primary index date was date
of referral for diagnostic MSLT. Sites identified all cases diagnosed
from April 1, 2009 until the end of 2015, but this varied by site
based on feasibility (Table 1). The Netherlands required consent
from cases because of the need to collect data from both GPs as
well as the National Public Health Agency.
Up to 20 controls were matched to each case by site on age
(year of birth), sex and index date. As per protocol, controls were
selected from the population giving rise to the cases, identification
could be implemented in different ways based on feasibility and
health care structure. Ontario, Valencia, Catalonia, the Netherlands,Table 2
Narcolepsy case characteristics for the case-control and case-coverage analysis by study s
Netherlands Switzerland Spain, Cat
Children
Total cases/controls [N] 22*/205 22/132 5/100
Brighton level [%]
1 31.8 36.4 0
2 68.2 54.5 100
3 0 9.1 0
4a 0 0 0
Cataplexy present [%]** 95.5 86.4 100
Age at diagnosis [%]
<6 yrs 4.5 0 0
6–12 yrs 50.0 40.9 60.0
13–18 yrs 45.5 59.1 40.0
pH1N1 vaccination coverage cases [%]
Focetria-MF59 0 0 0
Pandemrix- and Arepanrix-AS03 31.8* 0 0
Unadjuvanted 0 0 0
pH1N1 vaccination coverage controls [%]
Focetria-MF59 3.4 3.8 0
Pandemrix- and Arepanrix-AS03 0 0 0
Unadjuvanted 0 0 0
Adults
Total cases/controls [N] 32/280 13/260
Brighton level [%]
1 53.1 7.7
2 31.3 84.6
3 12.5 7.7
4a 3.1 0
Cataplexy present [%]** 78.1 84.6
Age at diagnosis [%]
19–59 yrs 96.9 100
60+ 3.1 0
pH1N1 vaccination coverage cases [%]
Focetria-MF59 3.1 0
Pandemrix- and Arepanrix-AS03 0 0
Unadjuvanted 0 0
pH1N1 vaccination coverage controls [%]
Focetria-MF59 2.5 0
Pandemrix- and Arepanrix-AS03 0 0.4
Unadjuvanted 0 0.4
*Nine child cases were included in a separate case-coverage study for reasons described i
coverage study and 13 from the case-control study.
**By definition, Brighton Collaboration (BC) narcolepsy case levels 1 and 2 have unamb
inclusion in this study, children ages < 16 years are BC levels 1 and 2, children 17–18 ye
**Cell counts that represent case counts of five or fewer (for Ontario, Canada) or two or
Therefore these are represented as range (i.e.  n).
Please cite this article in press as: Weibel D et al. Narcolepsy and adjuvanted
Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.08.008and Taiwan sampled controls from population-based health record
databases. Argentina identified controls from primary care facili-
ties in the same geographic area as the cases. Switzerland recruited
controls from the same hospitals as cases, using auxiliary diseases
not related to vaccination.
2.3.2. Exposure
The main exposure of interest was adjuvanted pH1N1 vaccina-
tion (i.e., Pandemrix-AS03, Arepanrix-AS03 or Focetria-MF59). We
obtained information on vaccines similarly for cases and controls
from medical records, vaccination registries, insurance databases,
or vaccination cards. Only written or electronic records of immu-
nization were accepted. Risk windows for pH1N1 vaccine exposure
were any time prior to index date and further split in: 1–180 days,
181 days–2 years, and >2 years before index date. The Ontario site
provided the only data for Arepanrix-AS03; hence, there was no
pooling of the Arepanrix-AS03 data as Ontario was unique. Taiwan,
Argentina, the Netherlands, Switzerland, Valencia, and Catalonia
contributed data for Focetria-MF59. The Netherlands, Switzerland,
and Valencia contributed data for Pandemrix-AS03.ite.
alonia Spain, Valencia Argentina Canada, Ontario Taiwan Total
11/220 11/86 28/55 51/510 150/1308
0 9.1 0 7.8 13.3
63.6 81.8 57.1 66.7 65.3
36.4 9.1 42.9 17.7 18.7
0 0 0 7.8 2.7
63.6 90.9 57.1 72.5 76.7
9.1 0 0 0 1.3
90.9 63.6 21.4 37.3 43.3
0 36.4 78.6 62.7 55.3
0 27.3 0 45.1 18.4
0 0 17.9 0 33.1
0 0 0 45.1 16.3
2.3 10.5 0 0.6 2.1
0 0 17.3 0 0.8
0 0 0 37.3 15.9
36/720 4/12 39/75 86/860 210/2207
0 0 0 1.2 9.1
38.9 50.0 25.6 39.5 38.6
55.6 50.0 69.2 31.4 38.6
5.6 0 12.8 27.9 15.2
41.7 50.0 25.6 41.9 47.2
97.2 100 100 100 99.0
2.8 0 0 0 1.0
0 0 0 14.0 6.2
0 0 12.8 0 1.4
2.8 0 0 14.0 6.2
0.1 33.3 0 1.1 1.0
1.4 0 8.0 0 0.8
0 0 0 8.8 3.5
n the methods. The child case total for the Netherlands includes nine from the case-
iguous cataplexy; BC narcolepsy case levels 3 and 4 may not have cataplexy. For
ars are BC levels 1–4, and adults  19 years are BC levels 1–4.
fewer (for Taiwan) cannot be displayed due to national patient privacy regulations.
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Odds ratios (OR) and 95% confidence intervals (CI) were calcu-
lated using conditional logistic regression or exact logistic regres-
sion if zero cells occurred. The reference category for estimation
of the pH1N1 vaccination effect was no pH1N1 vaccination. Due
to low exposure levels, we only present the analysis for the risk
window of any time prior to the index date because this provided
the maximum power.
To address potential awareness bias in the European Union (EU)
sites, we analyzed data from two time periods, a ‘‘restricted” period
and a ‘‘total” period. The restricted period analysis included cases
from participating EU sites in the Netherlands, Valencia, Catalonia,
and Switzerland only when they were diagnosed prior to onset of
awareness about the narcolepsy signal in Europe (August 2010),
and also cases from sites outside the EU diagnosed anytime during
the entire study period. The total period analysis included cases
from all sites for the entire study period, including cases from EU
sites diagnosed after media attention.
We pooled data from sites using a hybrid approach (one stage
pooling of matched case and control pairs for EU sites and Argen-
tina, which could share data, and two-stage pooling with Taiwan
and Ontario, which shared case counts and coefficients which were
subsequently meta-analyzed with the one stage pooled data from
EU sites and Argentina) (Fig. 1). Children were defined as 18 years
of age and adults as 19 years. Due to incomplete pH1N1 vaccina-
tion information from GPs in children born between 2004 and
2009 in the Netherlands (because these children were vaccinated
at local health agencies instead of GPs where we obtained exposure
information for all study subjects), these cases and controls were
excluded from the case-control analysis. However, cases born
between 2004 and 2009 in the Netherlands were included in a post
hoc case-coverage analysis (see below). In Switzerland, only child
cases were included because of potential selection and information
biases that was detected in adult cases. (Tables 1 and 2). In addi-
tion to using diagnostic MSLT referral as index date, we conducted
sensitivity analyses using EDS onset date (requiring EDS starting
after March 31, 2009). We used SAS v9.2 and statistical significance
was set at p-value <0.05.2.4. Case coverage analysis
In the Netherlands, cases born from 2004 through 2009 were
analyzed using a case-coverage design. During the 2009 H1N1Fig. 2. Incidence rates of narcolepsy by age group and year from Sweden (left, a signal
Canada (2003–2013); British Columbia, Canada (2003–2013), Manitoba, Canada (2003–2
2013), the Netherlands (2003–2013); Sweden (2003–2013), Taiwan (2003–2012), Unite
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at Municipal Health Services, and not through their GPs. Vaccina-
tions for these children were registered in a nationwide database,
Influsys, managed by the National Public Health Institute. Exposure
in cases was therefore obtained from Influsys and exposure preva-
lence in the population for children born in the same year was
obtained by calendar week and year of birth and used in the anal-
ysis, similar to the method used in the United Kingdom by Stowe
et al. [27]. This post-hoc analytic approach allowed us to include
information from the Netherlands, where individual exposure data
was not available, to complement other data on Pandemrix-AS03.
2.5. Ethics committee approval
This study was conducted under the principles of the Helsinki
declaration [28]. Each site was responsible for obtaining appropri-
ate ethical approvals, the overall study was approved by the
Institutional Review Board at Cincinnati Children’s Hospital
Medical Center.
2.6. Role of the funding source
Two investigators (TS and FD) from the sponsoring organiza-
tion, the U.S. Centers for Disease Control and Prevention, partici-
pated in development of the study design, analysis and
interpretation of data, writing the report, and in the decision to
submit the paper for publication.
3. Results
3.1. Narcolepsy incidence rates analysis
540 million person-years from ten sites in seven countries con-
tributed to the narcolepsy IR analysis. In Sweden, a previously
identified signaling country, IRs increased significantly after the
start of its pH1N1 vaccination campaign for children 5–19 years
(IRR = 9.01; 95% CI 6.89–11.80) and adults 20–59 years (IRR =
1.69; 95% CI 1.46–1.95). From 2011 onwards, narcolepsy IRs
decreased in Sweden (Fig. 2). In other EU sites, narcolepsy IRs in
the post-vaccination period did not change significantly compared
to the pre-pH1N1 vaccination period. In Canada, where Arepanrix-
AS03 was used, no changes in IRs were observed in any province
sites in any age category. In Taiwan, pre-pH1N1 period narcolepsying country) and other study sites excluding Sweden (right, pooled data). Alberta,
010); Catalonia, Spain (2007–2013), Valencia, Spain (2009–2013), Denmark (2003–
d Kingdom (2003–2013).
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than in EU and Canadian sites (varying between 0.5 and 1.5 per
100,000 person-years) and we observed significant IR increases
in children 5–19 years (IRR = 2.50; 95% CI 1.46–4.28) and adults
20–59 years (IRR = 2.23; 95% CI 1.26–3.94) during wild-type
pH1N1 virus circulation prior to the vaccination campaign (also
previously presented in Dodd et al. [29]).3.2. Case-control and case-coverage analysis
According to information supplied to us by WHO and the man-
ufacturers of the three adjuvanted 2009 pH1N1 vaccines, these
vaccines were distributed in 47 countries. Many of these countries
reportedly only used small amounts of vaccine in their private
markets. Of these 47 countries, we selected 16 countries for poten-
tial participation in the study based upon our estimation of the
likelihood that they would meet our eligibility criteria. Ten of the
16 potential participating countries were deemed ineligible after
reviewing them against our eligibility criteria. (Of the sites we then
approached, only the province of Quebec in Canada declined par-
ticipation.) The six remaining countries participated in the case-
control study.
We included 360 narcolepsy cases with MSLT referral during
the study period: 150 were children 18 years and 210 were
adults 19 years, which were matched to a total of 3515 controls
(online supplement Table 1). For the restricted period analysis
(excluding cases diagnosed after awareness in the EU), 96 child
and 121 adult cases were included. For the total period analysis,
141 child and 210 adult cases were included. Nine child cases born
between 2004 and 2009 from the Netherlands (all diagnosed after
awareness) were only included in the case-coverage analysis.
Brighton Collaboration narcolepsy case definition diagnosis
levels varied by site, with EU sites having more level 1 cases
(23.40% in EU vs. 2.74% outside EU) and more cataplexy (73.06%
in EU vs. 50.68% outside EU) (Table 2). Median delay between
EDS onset and narcolepsy diagnosis was longer in adults compared
to children and varied between sites, with a very short delay for
Taiwan (online supplement Table 1). Shortening of delay was seen
in children in some sites in the EU but not outside the EU following
media and public awareness. In all sites, exposure to pH1N1 vac-
cine was low in cases and controls, except in Dutch children born
between 2004 and 2009, with seven out of nine cases exposed to
Pandemrix-AS03.
In the meta-analysis for the restricted period, exposure to any
type of adjuvanted pH1N1 vaccine was not associated with nar-
colepsy in children or adults. The OR of the restricted period anal-
ysis in children 18 years of age was 0.80 (95% CI 0.21–3.01) forFig. 3. Odds ratios (OR) for narcolepsy and 95% confidence intervals (CI) by vaccine b
Arepanrix-AS03: case-control study in Ontario, Canada. Focetria-MF59: two-stage ran
Valencia and Catalonia, Spain. Pandemrix-AS03: case-coverage study in the Netherlands
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The OR of the restricted period analysis in adults was 1.00 (95%
CI 0.21–4.81) for Arepanrix-AS03 and 0.71 (95% CI 0.16–3.14) for
Focetria-MF59. The risk with Pandemrix-AS03 could not be esti-
mated in the restricted period analysis due to the paucity of cases.
The total period analyses including all cases, as well as the sep-
arate case-coverage analysis in the Netherlands did not reveal an
increased risk of narcolepsy in children or adults. The OR of the
total period analysis in children 18 years was 0.80 (95% CI
0.21–3.01) for Arepanrix-AS03 and 1.40 (95% CI 0.43–4.64) for
Focetria-MF59. In the case-coverage analysis, of the nine child
cases born from 2004 through 2009, seven were exposed to
Pandemrix-AS03, yielding an OR of 1.44 (95% CI 0.30–6.98). The
OR of the total period analysis in adults was 1.00 (95% CI 0.21–
4.81) for Arepanrix-AS03, 0.65 (95% CI 0.14–2.95) for Focetria-
MF59, and 0.66 (95% CI 0–3.3) for Pandemrix-AS03 (Fig. 3).
Sensitivity analyses using EDS onset as index date for the total
period reduced the number of cases considerably, either due to an
EDS date before April 1, 2009 or missing EDS onset date. However,
this analysis did not substantially alter the main findings of the
total period analysis, which used MSLT referral as index date. For
Arepanrix-AS03, OR estimates lowered to 0.29 (95% CI 0.03–2.65)
in children and remained 1.00 (95% CI 0.05–18.9) in adults. For
Focetria-MF59, the pooled estimate ORs were 2.06 (95% CI: 0.63–
6.72) in children and 0.65 (95% CI: 0.14–2.95) in adults. For
Pandemrix-AS03, ORs were 0.48 (95% CI 0.15–1.58) in children
and 1.12 (95% CI 0–6.1) in adults.4. Discussion
The SOMNIA study, a multi-country effort that included data
from sites on four continents, did not find an increase in narcolepsy
IRs associated with pH1N1 vaccination campaigns (except in
Sweden, a previously identified signaling country) nor did it detect
significant associations between narcolepsy following any adju-
vanted pH1N1 vaccines studied. To our knowledge, this is the
largest and most geographically diverse study with the longest
study period examining the association between adjuvanted
pH1N1 vaccines and narcolepsy. Oil-in-water adjuvants like AS03
and MF59 increase immunogenicity of influenza vaccines making
them attractive (or possibly necessary) for use in future pandemic
influenza vaccines, and they may have the potential to improve the
performance of seasonal influenza vaccines [30]. Assessing the
safety of these adjuvants has substantial public health and clinical
importance.
In our study, the IR of narcolepsy increased in Sweden begin-
ning in summer 2010 and declined in 2011, especially in childrenrands in the total period analysis for children (18 years) and adults (19 years).
dom effects meta-analysis of data from Taiwan, Argentina, the Netherlands, and
for children and case-control study in Valencia, Spain, for adults.
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any of the other participating sites. However, in Taiwan, a site with
a very short lag time between symptom onset and diagnosis of nar-
colepsy, a significant increase in IR of narcolepsy was observed
during circulation of wild-type pH1N1 virus but prior to pH1N1
vaccination, a phenomenon also reported in China, which had
low (unadjuvanted) vaccination coverage [31].
Ontario, where vaccination coverage was 32.2% [32], provided
case-control data on Arepanrix-AS03; no association with nar-
colepsy was found in children or adults, which contrasts with a
prior finding from a study in Quebec, where a small increase in risk
was found, although with large confidence intervals [23]. Since
Arepanrix-AS03 has the same adjuvant and a similar pH1N1 anti-
gen as the Pandemrix-AS03 vaccine used in Finland and Sweden,
it appears that the association for Pandemrix-AS03 and narcolepsy
observed in some European countries is not likely due to the AS03
adjuvant or the pH1N1 antigen in the vaccine alone. Focetria-MF59
was not associated with narcolepsy in children or adults in this
study, although the upper limit of the confidence interval cannot
exclude a small increase in risk in children. This is consistent with
prior observations of a lack of association (or just a few case
reports) in countries using this vaccine [33]. Because of low vacci-
nation coverage in sites for Pandemrix-AS03, we were constrained
in our ability to evaluate the possibility of an association in our
case-control study; our data from the Netherlands are based on a
small number of children who were between six months and five
years of age at vaccination.
The SOMNIA study contributes to our understanding of the epi-
demiology of narcolepsy before, during, and after the 2009 H1N1
influenza pandemic and pH1N1 vaccination campaigns. Impor-
tantly, it contributes to the body of evidence regarding the possible
association between adjuvanted pH1N1 vaccines and narcolepsy as
an adverse event following immunization. Prior data, mostly from
Europe, predominantly involved Pandemrix-AS03 exposure and
included many cases diagnosed shortly after increased media
attention and public awareness. Inclusion of the cases diagnosed
in the time period immediately after heightened media attention,
may overestimate an association, which is supported by the simu-
lations of Wijnans et al. [34]. Awareness about a possible associa-
tion with Pandemrix-AS03 may have resulted in vaccinated cases
being diagnosed sooner than they normally would have been,
resulting in apparent clusters of narcolepsy [35]. We attempted
to address this potential bias by including countries outside the
EU and countries in the EU that experienced less media and public
awareness; we also conducted an analysis restricting cases in Eur-
ope to those diagnosed before attention arose. Additionally, we
minimized potential bias from accelerated diagnosis of vaccinated
cases by recruiting cases up to five years after knowledge of a pos-
sible association became widespread. The findings of our SOMNIA
study indicate that the impact of media and public awareness, and
the resulting detection bias, may have diminished over time. Our
risk estimates of narcolepsy following adjuvanted pH1N1 vaccina-
tion for the restricted period analysis compared to the total period
analysis did not differ substantially. This is in contrast to the prior
Vaccine Adverse Event Surveillance & Communication (VAESCO)
study of EU countries, which had a much shorter case accrual per-
iod [35]. Overall, our study did not find an increased risk of nar-
colepsy following vaccination with AS03- or MF59-adjuvanted
pH1N1 vaccines based on the total period analysis.
Although we did not detect any significant associations
between adjuvanted pH1N1 vaccination and narcolepsy beyond
Sweden, we acknowledge the overall trend of evidence of an
increased risk associated with Pandemrix-AS03 [5,14,15,23]. A bio-
logic mechanism to explain this observation has not been estab-
lished, but it has been postulated that an interaction involving
the immune responses to administration of Pandemrix-AS03 andPlease cite this article in press as: Weibel D et al. Narcolepsy and adjuvanted
Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.08.008infection with wild-type pH1N1 virus could be a contributing fac-
tor [20]. This would explain the apparent presence of an associa-
tion in Finland, Sweden and Norway where wild-type virus
circulated coincident with the vaccination program, whereas no
association was seen in Ontario where wild-type virus was no
longer circulating at the time of the vaccination program. We were
not able to address this hypothesis in the SOMNIA study, but it
remains a focus area that will likely require a global cooperative
research effort.
This retrospective and observational study has several limita-
tions. Despite multiple study sites, statistical power in the
restricted period analysis was limited due to fewer cases and low
pH1N1 vaccination coverage (online supplement Table 2). For
Focetria-MF59, the only country with high coverage in the at-risk
age group was Argentina, but the number of cases was low.
Although we used standardized case definitions, case misclassifica-
tion could have occurred as diagnostic procedures and information
capture differed across sites. Nonetheless, our application of the
Brighton Collaboration case definition criteria for all cases
decreased the likelihood of misclassification. Misclassification of
exposure could have happened from incomplete recording of
pH1N1 vaccinations due to lack of access to school vaccination
records in Taiwan. Non-exhaustive inclusion of cases in Ontario
(due to distance) and the Netherlands (timeliness of consent) led
to incomplete inclusion of cases at the data lock point. For the
Netherlands, where consent for study participation was needed,
vaccinated cases might be more likely to give consent (given public
awareness), which could overestimate the risk; however no signif-
icant association was observed. For Ontario, data collection had not
been totally completed by the end of the study, but this was not
related to vaccination status and therefore impacted power alone.
Selection bias was detected in Switzerland for the adult cases (not
for children), when we compared our cases to a published series of
exposed cases [36], demonstrating lack of inclusion of exposed
cases in adults – this led to exclusion of adult cases and controls
in Switzerland. Finally, although we used a common protocol
across all sites, it was necessary to provide flexibility for imple-
mentation at the local study site level for identifying cases and
controls. This might have introduced variability; however, the
main criterion in selecting controls was that they be representative
of individuals receiving pH1N1 vaccination in the general popula-
tion and that exposure information was obtained similarly for
cases and controls.5. Conclusion
We did not observe increases in population-based narcolepsy
IRs associated with pH1N1 vaccination campaigns at participating
sites, except for Sweden. In the case-control analysis, we did not
detect evidence of a significant increased risk of narcolepsy follow-
ing any of the adjuvanted pH1N1 vaccines in children or adults in
our study population, although upper limits of estimates do not
exclude small to moderate risks. The SOMNIA study highlights
the usefulness of international collaboration in the evaluation of
vaccine safety signals for rare adverse events. Using a common
protocol and methods reduces heterogeneity, permits contribution
of data from countries across the world, and allows for combining
data for increased statistical power necessary to address questions
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